



1102865-0046

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/813,336
Filing Date	March 29, 2004
First Named Inventor	Grimes, et al.
Art Unit	1653
Examiner Name	TBA
Attorney Docket Number	1102865-0046

Sheet

1

**U.S. PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
CK		5,607,676	3-04-1997	Gevas et al.	
		2003/0082643 A1	5-01-2003	Hudson et al.	
		2003/0232399 A1	12-18-2003	Robertson et al.	
		2003/0049698	3-13-2003	Wang	
		5,580,563	12-03-96	Tam et al.	
		5,110,911	5-5-1992	Samuel et al.	
		5,731,159	3-24-1998	Waldman	
		5,767,242	6-16-1998	Zimmermann et al.	
		5,869,045	2-9-1999	Hellstrom et al.	
		6,187,536 B1	2-13-2001	Weinberg et al.	
CK		6,251,581 B1	6-26-2001	Ullman et al.	
		6,320,022 B1	11-20, 2001	Cutitta et al.	
		6,696,262 B2	2-24-2004	Härkönen	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO 01/77685 A2	10-18-2001			
		WO 2004/023148	03-18-2004			

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		SUGANO et al., The Journal of Biological Chemistry, 1986, 11724-11729, Vol. 380	
		VARRO et al., Ann Clin Biochem, 2003, 472-480, Vol. 40	
		RAHIER et al., Biosynthesis of Gastrin, Gastroenterology, 1987, 1146-1152, Vol. 92	

NON PATENT LITERATURE DOCUMENTS			
_____	_____	KOKTHARY et al., Regulatory Peptides, 1987, 71-84, Vol. 17	
_____	_____	ARDILL et al., QJ Med, 1998, 739-742, Vol. 91	
_____	_____	SEVA, et al., Science, 1994, 410-412, Vol. 265	
_____	_____	SMITH et al., The British Journal of Surgery, 1998, 1285-1289, Vol. 85	
_____	_____	TODISCO et al., The Journal of Biological Chemistry, 1995, 28337-28341, Vol. 270	
_____	_____	WATSON et al., Br. J. Cancer, 1989, 554-558, Vol. 59	DUPLICATE ENTRY
_____	_____	VARRO et al., The Journal of Biological Chemistry, 1994, 20764-20770, Vol. 269	
_____	_____	DICKINSON et al., The Journal of Biological Chemistry, 1991, 334-338, Vol. 266	
_____	_____	KELLY et al., Journal of Gastroenterology and Hepatology, 1998, 208-214, Vol. 13	
_____	_____	Rehfeld et al., Cancer Research, 1989, 2840-2843, Vol. 49	
_____	_____	Smith et al., Gut, 2000, 820-824, Vol. 47	
_____	_____	WATSON et al., Cancer Research, 2001, 625-631, Vol. 61	DUPLICATE ENTRY
_____	_____	HUGHES et al., Digestive Diseases, 1976, 201-204, Vol. 21	
_____	_____	JAFFE, et al., Surgery, 1969, 633-639, Vol. 65	
_____	_____	DOCKRAY, et al., The Gastrins: Their Production and Biological Activities, 119-139	
_____	_____	SMITH et al., Alimentary Pharmacology & Therapeutics, 1231-1247, Vol. 14	
_____	_____	DICKINSON et al., Gastroenterology, 1995, 1384-1388, Vol. 109	
_____	_____	REHFELD ET AL., Biochimica et Biophysica Acta, 1972, 364-372, Vol. 285	
_____	_____	NEMETH ET AL., Gut, 1993, 90-95, Vol. 34	
_____	_____	VARDELL, ET AL., Experienta, 1983, 713-717, Vol. 39	
cf		WATSON, S. Exp. Opin. Invest. Drugs, 1995, 1253-1266, Vol. 4	
cf		WATSON, ET AL., Gastrin Receptors in Gastrointestinal Tumors, 1993, 1-91	CRC PRESS, Boca Raton, FL.
cf		CAPLIN, ET AL., Journal of Hepatology, 1999, 519-526, Vol. 30	
cf		HENWOOD, ET AL., British Journal of Surgery, 2001, 564-568, Vol. 88	
cf		WATSON, ET AL., Int. J. Cancer, 1998, 873-877, Vol. 75	
cf		WATSON, ET AL., Int. Cancer, 1999, 248-254, Vol. 81	

## NON PATENT LITERATURE DOCUMENTS

if		WATSON, ET AL., Cancer Research, 1996, 880-885, Vol. 56	
if		WATSON, ET AL., Cancer Research, 2001, 625-631, Vol. 61	
if		WATSON, ET AL., Reports, 1991, 866-871, Vol. 83, <i>J. Natl Cancer Inst</i>	
if		WATSON, ET AL., Growth Enhancing effects of Gastrin, 1998, 554-558, <i>Br. J. Cancer</i> Vol. 59	
if		WATSON, ET AL., Exp. Opin. Invest. Drugs, 1995, 1253-1266, Vol. 4	
		WATSON, ET AL., Human Progastrin Expression, 1996, 1918-1929, Vol. 98	
		WATSON, ET AL., Exp. Opin. Ther., 2001, 309-317, Vol. 1	
		HOFF, ET AL., Current Opinion in Oncology, 2002, 621-627, Vol. 14	
		GILLIAM, ET AL., EJSO, 2004, 536-543, Vol. 30	
if		KOVACS, ET AL, Gastroenterology, 1989, 1406-1413, Vol. 97	
		MAKISHIMA, ET AL., Faseb Journal, 1994, A92, Vol. 8 Abs-535	
		SMITH, ET AL., Clinical Cancer Research, 2000, 4719-4724, Vol. 6	
		HHS, MD, Arch Pathol Lab Med, 2001, 289-294, Vol. 125	
		COLE, Clinical Chemistry, 1997, 2233-2243, Vol. 43	
		FEURLE, ET AL, Pancreas, 1995, 281-286, Vol. 10	
		OHNING, ET AL., Peptides, 1994, 417-587, Vol. 15	
		KOVACS, ET AL., Peptides, 1996, 583-587, Vol. 17	
		OHNING, ET AL., The American Journal Physiological Society, 1996, G470-476	
		SIPPONEN, ET AL., Scand J Gastroenterol, 2002, 785-791, Vol. 7	
		DOCKRAY, ET AL., Gastroenterology, 1975, 222-230, Vol. 68	
		SMITH, ET AL., American Journal Physiology, 1996, R1078-R1084, Vol. 270	
		SMITH, ET AL., American Journal Physiology, 1995, R135-R141, Vol. 286	
		SMITH, ET AL., American Journal Physiology, 1994, R277-283, Vol. 266	
		YANAIHARA, ET AL., Gut Peptides, 1979, 26-33	
if		KOVACS, ET AL., American Journal Physiology, 1997, G399-403, Vol. 273 (2 Pt 1).	
if		VAANANEN ET AL., European J. Gastroenterology, 2003, 885-891, Vol. 15 (Pt 8).	





Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*(Use as many sheets as necessary)*


**Complete if Known**

Application Number	10/813,336
Filing Date	March 29, 2004
First Named Inventor	Grimes, S. et al.
Art Unit	1653
Examiner Name	Christine E. Foster
Attorney Docket Number	1102865-0046

Sheet		of	2
-------	--	----	---

## U. S. PATENT DOCUMENTS


[illegible]

Examiner Signature		Date Considered	9/28/05
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/813,336		
		Filing Date	March 29, 2004		
		First Named Inventor	Grimes et al.		
		Art Unit	1653		
		Examiner Name	Christine E. Foster		
Sheet	2	of	2	Attorney Docket Number	1102865-0046

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Kovacs, T.O. et al. (1997, Aug.) "Inhibition of sham feeding stimulated . . ." Am J Physiol. 273 (2 Pt 1): G399-403.	
		Vaananen H., et al. (2003), Aug.) "Non-endoscopic diagnosis of atrophic gastritis . . ." Eur J. Gastroenterol. 15(8) 885-891.	
		Du W., Xu Z., Ma X., Song L., and Schneider (2003, Dec.) "Biochip as a potential platform . . ." J Biotechnol. (2003, Dec.) 106 (1): 87-100.	
		Tetin S., Y., et al. (2004, Feb.) "Antibodies in diagnostic applications" Curr Pharm Biotechnol 5 (1): 9-16.	
		Onorato J.M., et al. (1998, Nov.) "Immunohistochemical and ELISA assays . . ." NY Acad Sci 854: 277-290.	
		Plested J.S. et al. (2003) Methods Mol Med 71: 243-261.	
		Rondeel J.M., (2002, May) "Immunofluorescence versus ELISA . . ." Expert Rev Mol Diagn. 2(3): 266-232.	
		Bailey G.S., (1994) "Radioimmunoassay of Peptides and Protein" Methods Mol Biol. 32: 449-459.	

Examiner Signature	<i>CFoster</i>	Date Considered	9/28/05
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.